Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry

You may also be interested in...



China's Big Cities Should Be First Priority For Pharma Companies - IMS

SHANGHAI- China's largest cities control the majority of the Chinese pharma market, and companies must decide city-specific sales strategies, according to the global healthcare data provider and consulting firm IMS Health

China's Big Cities Should Be First Priority For Pharma Companies - IMS

SHANGHAI- China's largest cities control the majority of the Chinese pharma market, and companies must decide city-specific sales strategies, according to the global healthcare data provider and consulting firm IMS Health

AstraZeneca Will Validate siRNA Delivery Technology For MDRNA In Shanghai Innovation Center

SHANGHAI - Bothell, Washington-headquartered MDRNA announced recently that the company will collaborate with AstraZeneca to validate MDRNA's small interfering RNA (siRNA) technology for systemic delivery in hepatocellular carcinoma, one of the company's preclinical oncology programs

Related Content

UsernamePublicRestriction

Register

SC074446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel